AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01769261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eligible, Internet
Description: Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
Study NCT01769261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eligibles, telephone
Description: Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
Study NCT01769261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non eligibles
Description: Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
Study NCT00501046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9g /day (3 times a day)
Study NCT00501046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: 9g /day (3 times a day)
Study NCT00393913 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
Study NCT03767296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine Hydrochloride 3 MG/ML
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)
Study NCT02370745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: This will be co infused with GLP-1 and intravenous amino acids
Study NCT02370745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids
Description: This will aim to deliver iso equivalent amount to the amino acids administered orally
Study NCT02072083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: via intranasal route 1 mcg/kg
Study NCT02072083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
Study NCT01885403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive respiratory parameter measurements
Study NCT04424888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-011
Description: WB-011 medical food product.
Study NCT04424888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules identical to those containing WB-011.
Study NCT04424888 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
Study NCT04424888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
Study NCT03767296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)
Study NCT01850862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collective group exercise program in patients with KOA
Study NCT01850862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orientation (without exercise)
Description: Orientation about osteoarthritis disease but without any exercise program
Study NCT04627142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: Tablet
Study NCT04627142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camptosar®
Description: Solution for infusion
Study NCT03298191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Those women will be given Magnesium Sulfate for tocolysis
Study NCT03298191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritodrine
Description: Those women will be given Ritodrine for tocolysis
Study NCT03298191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Description: Those women will be given Calcium Channel Blockers for tocolysis
Study NCT01011608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food Supplement
Description: Medical Food Supplement to be given in divided portions in morning, afternoon and evening
Study NCT01011608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard hospital food
Description: standard hospital diet ad. lib.
Study NCT04045717 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-FLAME 2.0 study
Description: SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
Study NCT05579912 — intervention group
Intervention type: PROCEDURE
Intervention: Esophageal and gastric resections requiring an anastomosis
Description: Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
Study NCT02325817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Description: Treat the side branch of bifurcation lesion with drug-eluting balloon
Study NCT02325817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated ballloon
Description: Treat the side branch of bifurcation lesion with uncoated balloon
Study NCT04300491 — intervention group
Intervention type: OTHER
Intervention: Suspension walking training
Description: Physiotherapy session, objective wlaking with body weight support using a specific device
Study NCT00259740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DENOSUMAB
Description: 120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
Study NCT03360357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided drills
Description: These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)
Study NCT03252327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sensory Integrations
Description: breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
Study NCT00896324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
Study NCT00896324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Neurofeedback Training
Description: Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
Study NCT00896324 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback Training (placebo / Sham)
Description: Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
Study NCT00217269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Stenting
Description: Endeavor Drug eluting stent
Study NCT00217269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Stenting
Description: Taxus Drug Eluting Stent
Study NCT01838928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT00290251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulipristal acetate 20 mg
Description: ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
Study NCT00290251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulipristal acetate 10 mg
Description: 10 mg given daily for three menstrual cycles or 90 - 102 days
Study NCT00290251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given once daily for 3 menstrual cycles or 90 - 102 days
Study NCT03605251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 low dose
Description: Oral administration for 12 or 36 weeks
Study NCT03605251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 high dose
Description: Oral administration for 12 or 36 weeks
Study NCT03605251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
Study NCT03874494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2-4 mg/day
Study NCT03874494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole 10-20 mg/day
Study NCT03653494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phrenic block
Description: phrenic block by 1% ropivacaine 5ml
Study NCT03653494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no phrenic block
Description: no phrenic block
Study NCT05361291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Inferior alveolar nerve block
Study NCT05361291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Inferior alveolar nerve block
Study NCT03447392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Education of Chinese Medicine
Description: Discharge Education of Integrated Traditional and Western Medicine
Study NCT04641091 — intervention group
Intervention type: DEVICE
Intervention: Multispectral Optoacustic Tomography (MSOT)
Description: non-invasive transcutaneous imaging of subcellular muscle components
Study NCT06322134 — intervention group
Intervention type: OTHER
Intervention: Drowning incident
Description: Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.
Study NCT03310944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT03310944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT03573024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
Study NCT03801941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing ATLAS device during evaluation at 4th day
Description: Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Study NCT03573024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
Study NCT04626635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7075
Description: Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
Study NCT04626635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered concomitantly Q3W by IV infusion or SC injection
Study NCT04626635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based doublet chemotherapy
Description: Administered IV Q3W
Study NCT04626635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered per protocol
Study NCT04626635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine-tipiracil
Description: Administered per protocol
Study NCT03523858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
Study NCT02894398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons
Study NCT02894398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
Study NCT02894398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
Study NCT02412748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTF Intervention
Description: The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
Study NCT02412748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Literacy Program
Description: The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
Study NCT00130117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Description: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Study NCT00130117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Contraceptive Pills (OCPs)
Description: Sprintec taken orally once daily.
Study NCT00130117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCPs)
Description: Sprintec taken orally once daily.
Study NCT00130117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (no active medication)
Study NCT02994173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Current clinical practice, used as a control in this study
Study NCT02994173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.25
Description: dosage
Study NCT02994173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.5
Description: dosage
Study NCT02994173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine 0.75
Description: dosage
Study NCT04222686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Arginine
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study NCT04222686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan Potassium
Description: 100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
Study NCT04237155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will complete a verbal material scoring questionnaire
Study NCT04237155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive tests
Description: Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
Study NCT00995306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide (Zucapsaicin)
Description: Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks
Study NCT03654235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education
Description: 6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
Study NCT03654235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
Study NCT03654235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care in Primary Care Physiotherapy Units
Description: Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise
Study NCT02047981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Study NCT02047981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Study NCT03641703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
Study NCT02488096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-Guided Biopsy
Description: The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
Study NCT02488096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI + TRUS-Guided Biopsy
Description: A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI.